Will NVIDIA Return to Its 52-Week High?
NVIDIA (NASDAQ:NVDA) has been among the best-performing investments of the…
Sell
17
RHCGF Quote, Financials, Valuation and Earnings
Last price:
$1.41
Seasonality move
:
-11.48%
Day range:
$1.41 - $1.41
52-week range:
$1.40 - $3.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.34x
Volume:
--
Avg. volume:
1.3K
1-year change:
-57.91%
Market cap:
$705M
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RHCGF
Ryman Healthcare
|
-- | -- | -- | -- | -- |
|
AROAF
Aroa Biosurgery
|
-- | -- | -- | -- | -- |
|
FSPKF
Fisher & Paykel Healthcare
|
-- | -- | -- | -- | -- |
|
PFGTF
Pacific Edge
|
-- | -- | -- | -- | -- |
|
PRCXF
Green Cross Health
|
-- | -- | -- | -- | -- |
|
SMGRF
Summerset Group Holdings
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RHCGF
Ryman Healthcare
|
$1.41 | -- | $705M | -- | $0.00 | 0% | -- |
|
AROAF
Aroa Biosurgery
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
FSPKF
Fisher & Paykel Healthcare
|
$16.35 | -- | $9.6B | 62.70x | $0.11 | 1.54% | 8.96x |
|
PFGTF
Pacific Edge
|
$0.08 | -- | $64.1M | -- | $0.00 | 0% | 4.38x |
|
PRCXF
Green Cross Health
|
$0.70 | -- | $100.5M | 13.94x | $0.01 | 0% | 0.32x |
|
SMGRF
Summerset Group Holdings
|
$9.45 | -- | $2.3B | 11.05x | $0.08 | 1.55% | 11.74x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RHCGF
Ryman Healthcare
|
-- | -0.138 | -- | -- |
|
AROAF
Aroa Biosurgery
|
-- | 0.000 | -- | -- |
|
FSPKF
Fisher & Paykel Healthcare
|
7.25% | 1.233 | 0.64% | 0.99x |
|
PFGTF
Pacific Edge
|
7.56% | -4.587 | 4.07% | 4.87x |
|
PRCXF
Green Cross Health
|
47.81% | 0.000 | 83.12% | 0.44x |
|
SMGRF
Summerset Group Holdings
|
36.6% | -0.028 | 43.27% | 0.11x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RHCGF
Ryman Healthcare
|
-- | -- | -- | -- | -- | -- |
|
AROAF
Aroa Biosurgery
|
-- | -- | -- | -- | -- | -- |
|
FSPKF
Fisher & Paykel Healthcare
|
-- | -- | 8.89% | 9.85% | -- | -- |
|
PFGTF
Pacific Edge
|
-- | -- | -54.77% | -56.46% | -- | -- |
|
PRCXF
Green Cross Health
|
-- | -- | 4.37% | 7.12% | -- | -- |
|
SMGRF
Summerset Group Holdings
|
-- | -- | 5.8% | 12.83% | -- | -- |
Ryman Healthcare vs. Competitors
-
Which has Higher Returns RHCGF or AROAF?
Aroa Biosurgery has a net margin of -- compared to Ryman Healthcare's net margin of --. Ryman Healthcare's return on equity of -- beat Aroa Biosurgery's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RHCGFRyman Healthcare-- -- -- AROAFAroa Biosurgery-- -- -- -
What do Analysts Say About RHCGF or AROAF?
Ryman Healthcare has a consensus price target of --, signalling downside risk potential of --. On the other hand Aroa Biosurgery has an analysts' consensus of -- which suggests that it could fall by --. Given that Ryman Healthcare has higher upside potential than Aroa Biosurgery, analysts believe Ryman Healthcare is more attractive than Aroa Biosurgery.
Company Buy Ratings Hold Ratings Sell Ratings RHCGFRyman Healthcare0 0 0 AROAFAroa Biosurgery0 0 0 -
Is RHCGF or AROAF More Risky?
Ryman Healthcare has a beta of 0.598, which suggesting that the stock is 40.193% less volatile than S&P 500. In comparison Aroa Biosurgery has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RHCGF or AROAF?
Ryman Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aroa Biosurgery offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ryman Healthcare pays -- of its earnings as a dividend. Aroa Biosurgery pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RHCGF or AROAF?
Ryman Healthcare quarterly revenues are --, which are smaller than Aroa Biosurgery quarterly revenues of --. Ryman Healthcare's net income of -- is lower than Aroa Biosurgery's net income of --. Notably, Ryman Healthcare's price-to-earnings ratio is -- while Aroa Biosurgery's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ryman Healthcare is -- versus -- for Aroa Biosurgery. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHCGFRyman Healthcare-- -- -- -- AROAFAroa Biosurgery-- -- -- --
-
Which has Higher Returns RHCGF or FSPKF?
Fisher & Paykel Healthcare has a net margin of -- compared to Ryman Healthcare's net margin of --. Ryman Healthcare's return on equity of -- beat Fisher & Paykel Healthcare's return on equity of 9.85%.
Company Gross Margin Earnings Per Share Invested Capital RHCGFRyman Healthcare-- -- -- FSPKFFisher & Paykel Healthcare-- -- $1.3B -
What do Analysts Say About RHCGF or FSPKF?
Ryman Healthcare has a consensus price target of --, signalling downside risk potential of --. On the other hand Fisher & Paykel Healthcare has an analysts' consensus of -- which suggests that it could fall by --. Given that Ryman Healthcare has higher upside potential than Fisher & Paykel Healthcare, analysts believe Ryman Healthcare is more attractive than Fisher & Paykel Healthcare.
Company Buy Ratings Hold Ratings Sell Ratings RHCGFRyman Healthcare0 0 0 FSPKFFisher & Paykel Healthcare0 0 0 -
Is RHCGF or FSPKF More Risky?
Ryman Healthcare has a beta of 0.598, which suggesting that the stock is 40.193% less volatile than S&P 500. In comparison Fisher & Paykel Healthcare has a beta of 1.077, suggesting its more volatile than the S&P 500 by 7.655%.
-
Which is a Better Dividend Stock RHCGF or FSPKF?
Ryman Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fisher & Paykel Healthcare offers a yield of 1.54% to investors and pays a quarterly dividend of $0.11 per share. Ryman Healthcare pays -- of its earnings as a dividend. Fisher & Paykel Healthcare pays out 109.73% of its earnings as a dividend.
-
Which has Better Financial Ratios RHCGF or FSPKF?
Ryman Healthcare quarterly revenues are --, which are smaller than Fisher & Paykel Healthcare quarterly revenues of --. Ryman Healthcare's net income of -- is lower than Fisher & Paykel Healthcare's net income of --. Notably, Ryman Healthcare's price-to-earnings ratio is -- while Fisher & Paykel Healthcare's PE ratio is 62.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ryman Healthcare is -- versus 8.96x for Fisher & Paykel Healthcare. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHCGFRyman Healthcare-- -- -- -- FSPKFFisher & Paykel Healthcare8.96x 62.70x -- --
-
Which has Higher Returns RHCGF or PFGTF?
Pacific Edge has a net margin of -- compared to Ryman Healthcare's net margin of --. Ryman Healthcare's return on equity of -- beat Pacific Edge's return on equity of -56.46%.
Company Gross Margin Earnings Per Share Invested Capital RHCGFRyman Healthcare-- -- -- PFGTFPacific Edge-- -- $27.9M -
What do Analysts Say About RHCGF or PFGTF?
Ryman Healthcare has a consensus price target of --, signalling downside risk potential of --. On the other hand Pacific Edge has an analysts' consensus of -- which suggests that it could fall by --. Given that Ryman Healthcare has higher upside potential than Pacific Edge, analysts believe Ryman Healthcare is more attractive than Pacific Edge.
Company Buy Ratings Hold Ratings Sell Ratings RHCGFRyman Healthcare0 0 0 PFGTFPacific Edge0 0 0 -
Is RHCGF or PFGTF More Risky?
Ryman Healthcare has a beta of 0.598, which suggesting that the stock is 40.193% less volatile than S&P 500. In comparison Pacific Edge has a beta of -2.263, suggesting its less volatile than the S&P 500 by 326.301%.
-
Which is a Better Dividend Stock RHCGF or PFGTF?
Ryman Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Edge offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ryman Healthcare pays -- of its earnings as a dividend. Pacific Edge pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RHCGF or PFGTF?
Ryman Healthcare quarterly revenues are --, which are smaller than Pacific Edge quarterly revenues of --. Ryman Healthcare's net income of -- is lower than Pacific Edge's net income of --. Notably, Ryman Healthcare's price-to-earnings ratio is -- while Pacific Edge's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ryman Healthcare is -- versus 4.38x for Pacific Edge. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHCGFRyman Healthcare-- -- -- -- PFGTFPacific Edge4.38x -- -- --
-
Which has Higher Returns RHCGF or PRCXF?
Green Cross Health has a net margin of -- compared to Ryman Healthcare's net margin of --. Ryman Healthcare's return on equity of -- beat Green Cross Health's return on equity of 7.12%.
Company Gross Margin Earnings Per Share Invested Capital RHCGFRyman Healthcare-- -- -- PRCXFGreen Cross Health-- -- $198.2M -
What do Analysts Say About RHCGF or PRCXF?
Ryman Healthcare has a consensus price target of --, signalling downside risk potential of --. On the other hand Green Cross Health has an analysts' consensus of -- which suggests that it could fall by --. Given that Ryman Healthcare has higher upside potential than Green Cross Health, analysts believe Ryman Healthcare is more attractive than Green Cross Health.
Company Buy Ratings Hold Ratings Sell Ratings RHCGFRyman Healthcare0 0 0 PRCXFGreen Cross Health0 0 0 -
Is RHCGF or PRCXF More Risky?
Ryman Healthcare has a beta of 0.598, which suggesting that the stock is 40.193% less volatile than S&P 500. In comparison Green Cross Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RHCGF or PRCXF?
Ryman Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Green Cross Health offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. Ryman Healthcare pays -- of its earnings as a dividend. Green Cross Health pays out 441.92% of its earnings as a dividend.
-
Which has Better Financial Ratios RHCGF or PRCXF?
Ryman Healthcare quarterly revenues are --, which are smaller than Green Cross Health quarterly revenues of --. Ryman Healthcare's net income of -- is lower than Green Cross Health's net income of --. Notably, Ryman Healthcare's price-to-earnings ratio is -- while Green Cross Health's PE ratio is 13.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ryman Healthcare is -- versus 0.32x for Green Cross Health. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHCGFRyman Healthcare-- -- -- -- PRCXFGreen Cross Health0.32x 13.94x -- --
-
Which has Higher Returns RHCGF or SMGRF?
Summerset Group Holdings has a net margin of -- compared to Ryman Healthcare's net margin of --. Ryman Healthcare's return on equity of -- beat Summerset Group Holdings's return on equity of 12.83%.
Company Gross Margin Earnings Per Share Invested Capital RHCGFRyman Healthcare-- -- -- SMGRFSummerset Group Holdings-- -- $2.6B -
What do Analysts Say About RHCGF or SMGRF?
Ryman Healthcare has a consensus price target of --, signalling downside risk potential of --. On the other hand Summerset Group Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Ryman Healthcare has higher upside potential than Summerset Group Holdings, analysts believe Ryman Healthcare is more attractive than Summerset Group Holdings.
Company Buy Ratings Hold Ratings Sell Ratings RHCGFRyman Healthcare0 0 0 SMGRFSummerset Group Holdings0 0 0 -
Is RHCGF or SMGRF More Risky?
Ryman Healthcare has a beta of 0.598, which suggesting that the stock is 40.193% less volatile than S&P 500. In comparison Summerset Group Holdings has a beta of -0.401, suggesting its less volatile than the S&P 500 by 140.118%.
-
Which is a Better Dividend Stock RHCGF or SMGRF?
Ryman Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Summerset Group Holdings offers a yield of 1.55% to investors and pays a quarterly dividend of $0.08 per share. Ryman Healthcare pays -- of its earnings as a dividend. Summerset Group Holdings pays out 9.87% of its earnings as a dividend. Summerset Group Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHCGF or SMGRF?
Ryman Healthcare quarterly revenues are --, which are smaller than Summerset Group Holdings quarterly revenues of --. Ryman Healthcare's net income of -- is lower than Summerset Group Holdings's net income of --. Notably, Ryman Healthcare's price-to-earnings ratio is -- while Summerset Group Holdings's PE ratio is 11.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ryman Healthcare is -- versus 11.74x for Summerset Group Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHCGFRyman Healthcare-- -- -- -- SMGRFSummerset Group Holdings11.74x 11.05x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will JP Morgan’s AI Advisor Be a Winner?
JPMorgan Chase is rolling out “JPM WealthAI for high-net-worth clients.…
Is Revolve Group Stock a Buy, Sell or Hold?
Recently, Revolve Group (NYSE:RVLV) management delivered some fairly positive business…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
